Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-019-02298-9
Abstract: BackgroundCheckpoint inhibitors are first-line therapies in melanoma, but safety in older adults has not yet been assessed. Ipilimumab improves survival, but immunologic-related adverse events (AEs) can be threatening, and its use in elderly people raises… read more here.
Keywords: melanoma; treated ipilimumab; elderly patients; years treated ... See more keywords